论文部分内容阅读
目的:检测凋亡相关蛋白Bcl-xL、Bcl-Xs/L以及Bcl-6在骨肉瘤中的表达,并探讨其与骨肉瘤预后的关系。方法:应用免疫组化方法检测Bcl-xL、Bcl-Xs/L以及Bcl-6在41例骨肉瘤组织中的表达,并分析其与无瘤生存率及生存时间的关系。结果:Bcl-xL、Bcl-Xs/L在骨肉瘤组织中表达的阳性率分别为53.7%和75.6%,而Bcl-6为阴性表达,是否行术前化疗不影响Bcl-xL的表达(P>0.05),Bcl-xL表达阳性者无瘤生存率较阴性者低(P<0.01),而Bcl-Xs/L表达与复发转移及无瘤生存率无相关关系。结论:Bcl-xL、Bcl-Xs/L在骨肉瘤中有不同程度的表达,Bcl-xL的表达与预后相关,Bcl-xL阳性表达者复发、转移率高,无瘤生存率低,这与Bcl-xL抑制骨肉瘤细胞凋亡导致化疗耐药的特性相关。
OBJECTIVE: To detect the expression of Bcl-xL, Bcl-Xs / L and Bcl-6 in osteosarcoma and to investigate their relationship with the prognosis of osteosarcoma. Methods: The expressions of Bcl-xL, Bcl-Xs / L and Bcl-6 in 41 cases of osteosarcoma were detected by immunohistochemistry. The relationship between Bcl-xL, Bcl-6 and Bcl- Results: The positive rates of Bcl-xL and Bcl-Xs / L expression in osteosarcoma were 53.7% and 75.6%, respectively, while the expression of Bcl-6 was negative. The preoperative chemotherapy did not affect the expression of Bcl-xL > 0.05). The Bcl-xL positive patients had lower tumor-free survival rate than the negative ones (P <0.01). However, there was no correlation between Bcl-Xs / L expression and tumor recurrence and metastasis. Conclusion: The expression of Bcl-xL and Bcl-Xs / L in osteosarcoma is different, the expression of Bcl-xL is related to the prognosis, the recurrence of Bcl-xL is high, the rate of tumor-free survival is low, Bcl-xL inhibits osteosarcoma cell apoptosis leading to chemoresistance.